Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/185201
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMao, Xiaoman-
dc.contributor.authorCalero Pérez, Pilar-
dc.contributor.authorMontpeyó, David-
dc.contributor.authorBruna, Jordi-
dc.contributor.authorYuste, Victor J.-
dc.contributor.authorCandiota, Ana Paula-
dc.contributor.authorLorenzo, Julia-
dc.contributor.authorNovio, Fernando-
dc.contributor.authorRuiz Molina, Daniel-
dc.date.accessioned2022-04-28T14:25:29Z-
dc.date.available2022-04-28T14:25:29Z-
dc.date.issued2022-04-05-
dc.identifier.issn2079-4991-
dc.identifier.urihttp://hdl.handle.net/2445/185201-
dc.description.abstractCisplatin has been described as a potent anticancer agent for decades. However, in the case of glioblastomas, it is only considered a rescue treatment applied after the failure of second-line treatments. Herein, based on the versatility offered by coordination chemistry, we engineered nanoparticles by reaction of a platinum (IV) prodrug and iron metal ions showing in vitro dual pH- and redox-sensitivity, controlled release and comparable cytotoxicity to cisplatin against HeLa and GL261 cells. In vivo intranasal administration in orthotopic preclinical GL261 glioblastoma tumor-bearing mice demonstrated increased accumulation of platinum in tumors, leading in some cases to complete cure and prolonged survival of the tested cohort. This was corroborated by a magnetic resonance imaging follow-up, thus opening new opportunities for intranasal glioblastoma therapies while minimizing side effects. The findings derived from this research showed the potentiality of this approach as a novel therapy for glioblastoma treatment.-
dc.format.extent22 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherMDPI-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/nano12071221-
dc.relation.ispartofNanomaterials, 2022, vol. 12, num. 7-
dc.relation.urihttps://doi.org/10.3390/nano12071221-
dc.rightscc by (c) Mao, Xiaoman et al, 2022-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))-
dc.subject.classificationGlioma-
dc.subject.classificationNanopartícules-
dc.subject.otherGliomas-
dc.subject.otherNanoparticles-
dc.titleIntranasal Administration of Catechol-Based Pt(IV) Coordination Polymer Nanoparticles for Glioblastoma Therapy-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.date.updated2022-04-28T10:02:16Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid35407338-
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
nanomaterials-12-01221-v2.pdf3.5 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons